In re: Akorn, Inc.

CourtDistrict Court, D. Delaware
DecidedSeptember 22, 2021
Docket1:20-cv-01254
StatusUnknown

This text of In re: Akorn, Inc. (In re: Akorn, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: Akorn, Inc., (D. Del. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE: AKORN, INC., et al., ) Chapter 11 ) Case No. 20-11177 (KBO) Debtors. ) (Jointly Administered) 1199SEIU NATIONAL BENEFIT FUND, ) et al., ) ) Appellants, ) ) v. ) ) C.A. No. 20-1254 (MN) AKORN, INC., et al., ) ) Appellees. )

MEMORANDUM OPINION

Leslie B. Spoltore, OBERMAYER REBMANN MAXWELL & HIPPEL LLP, Wilmington, DE; Edmond M. George, Turner N. Falk, OBERMAYER REBMANN MAXWELL & HIPPEL LLP, Philadelphia, PA – Counsel to 1199SEIU National Benefit Fund, 1199SEIU Greater New York Benefit Fund, 1199SEIU National Benefit Fund for Home Care Workers, 1199SEIU Licensed Practical Nurses Welfare Fund, AFSCME District Council 47 Health and Welfare Fund, and Sergeants Benevolent Association Health and Welfare Fund.

Paul N. Heath, Amanda R. Steele, Brett M. Haywood, RICHARDS LAYTON & FINGER, P.A., Wilmington, DE; George W. Hicks, Jr., Andrew C. Lawrence, KIRKLAND & ELLIS LLP, Washington DC – Counsel to Akorn, Inc.

September 22, 2021 Wilmington, Delaware Meee llecvbesei N , U.S. DISTRICT JUDGE: Pending before the Court is an appeal by 1199SEIU National Benefit Fund, 1199SETU Greater New York Benefit Fund, 1199SEIU National Benefit Fund for Home Care Workers, 1199SEIU Licensed Practical Nurses Welfare Fund, AFSCME District Council 47 Health and Welfare Fund, and Sergeants Benevolent Association Health and Welfare Fund (“Appellants”) from the Bankruptcy Court’s September 4, 2020 Order Confirming the Modified Joint Chapter 11 Plan of Akorn, Inc. and its Debtor Affiliates (B.D.I. 673) (Ex. P)! (“Confirmation Order”). Appellants hold unsecured, unliquidated litigation claims against debtor Akorn, Inc and certain affiliates (““Akorn” or “Debtors”) which depend on the outcome of contested antitrust claims pending in multidistrict litigation. Seeking to reverse the Confirmation Order, and presumably overturn the plan in toto, Appellants have asserted no less than fifteen errors on appeal. (See D.I. 26 at 7-9). Although it is unfortunate that Appellants may not receive a distribution under the confirmed plan, their attacks on the plan confirmation process are unavailing. For the reasons set forth herein, the Court will affirm the Confirmation Order. I. BACKGROUND A. Events Leading to Chapter 11 Akorn is a specialty generic pharmaceutical company that develops, manufactures, and markets various generic and branded prescription pharmaceuticals, over-the-counter consumer health products, and animal health pharmaceuticals. (See Ex. J at 1). Originally founded in 1971, through strategic mergers and acquisitions Akorn grew into a company worth hundreds of millions of dollars. (See id.). In April 2017, Akorn agreed to merge with a German corporation, Fresenius Kabi AG (“Fresenius”) in a transaction that would make Akorn a wholly-owned subsidiary of

The docket of the chapter 11 cases, captioned Jn re Akorn, Inc., et al., Case No. 20-11177 (KBO) (Bankr. D. Del.) is cited herein as “B.D.I. _.” “Ex.” refers to the exhibits filed with Appellants’ opening brief (D.I. 26).

Fresenius. (See id. at 30). Fresenius pursued the transaction notwithstanding that certain parties, including Appellants, had named Akorn as one of dozens of defendants in antitrust litigation. See In re Generic Pharms. Pricing Antitrust Litig., No. 2:16-md-02724-CMR (E.D. Pa. Aug. 5, 2016). The Fresenius transaction would have provided substantial value to Akorn shareholders. (See id. at 30, 37). The agreement authorized Fresenius to terminate the merger in specified circumstances, including if Akorn suffered a “material adverse effect” on its business. (See id. at 30). Following the announcement of the Fresenius merger, Akorn’s financial performance

began to deteriorate. (See id. at 30-31). In November 2017, Fresenius informed Akorn that it had received anonymous letters alleging data-integrity- and regulatory-related deficiencies at certain Akorn facilities. (See id. at 31). Fresenius publicly revealed in February 2018 that it had initiated an investigation into the matter, and in April 2018, Fresenius informed Akorn that it would terminate the merger. (See id.) In response, Akorn filed suit against Fresenius in Delaware, seeking performance of the merger agreement. (See id.) Fresenius counterclaimed, and in October 2018, the Delaware Chancery Court concluded that Fresenius validly terminated the agreement because Akorn had suffered a “material adverse effect.” (See id. at 32-33). Akorn faced related litigation from its shareholders. Some brought class-action securities claims alleging that Akorn and its management had misstated or omitted material information about its data-integrity controls and

compliance with FDA regulations. (See id. at 33). The parties reached a settlement agreement. (See id. at 34; see also Ex. A, Ex. B). As part of the settlement agreement, Akorn placed into escrow approximately $30 million in proceeds from its directors and officers (“D&O”) insurance policies, a certain number of shares of Akorn common stock, and certain “contingent value rights.”2 (See Ex. J at 34-35).

2 Other shareholders brought class-action derivative lawsuits, including in Louisiana state court. See Kogut v. Akorn, Inc., No. 646,174 (La. 19th. Dist. Ct.). That Louisiana class- action lawsuit ended with a settlement, which includes a broad release provision that In November 2018, soon after the Delaware Chancery Court issued its decision in the Fresenius litigation, Akorn received notices from several of its secured lenders stating that the court’s “material adverse effect” determination could have consequences under Akorn’s loan agreements – including a declaration by the lenders of an event of default, which would have authorized them to cancel the credit facilities and to demand immediate repayment of outstanding balances (approximately $850 million). (See id. at 37; Ex. L (9/1/2020 Tr.) at 13, 19). Akorn negotiated a standstill agreement with the lenders to give the Debtors breathing room to explore

their options. (See Ex. J. at 37; see also Ex. C (original term-loan credit agreement); Ex. D (original standstill agreement); Ex. E (first amendment to standstill agreement); Ex. F (second amendment to standstill agreement). In 2019, with the standstill in effect, Akorn worked with an investment bank to identify parties with sufficient capital to fully refinance or to pay down Akorn’s loans. (See Ex. J at 38). During that period, Akorn began to stabilize its business and earn revenue. (See id. at 39). The Debtors credited the efforts of senior executives who then received bonuses. (See Ex. M (9/2/2020 Tr.) at 36-43). In total, 32 prospective investors were contacted and 22 of them expressed interest. (See Ex. J at 38). Those prospective investors conducted due diligence, and Akorn held board meetings with its investment bank on a weekly or bi-weekly basis to discuss the options. (See id.;

9/1/2020 Tr. at 18 (Debtors’ investment banker explaining: “I would say we probably had the most number of board meetings in this case that I’ve ever had in my career.”). Ultimately, none of the prospective investors could refinance Akorn’s capital structure to the degree required. (See Ex. J at 38; 9/1/2020 Tr. at 13-38).

applies to the named plaintiff, Akorn, and every Akorn shareholder. (See D.I. 5-29). In light of that provision, other courts have dismissed derivative claims related to the events that led to the failed Fresenius merger. See Trsar v. Akorn, Inc., No. 18-cv-7374 (N.D. Ill.); Pulchinski v. Abramowitz et al., 2019CH11186 (Ill. Cir. Ct.); Booth Family Trust v. Kapoor, 2019CH12793 (Ill. Cir. Ct.); see also D.I. 5-30; D.I. 5-31; D.I. 5-32). Beginning in December 2019, Akorn pivoted toward pursuing a sale of its business. (See Ex. J at 39).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Norwest Bank Worthington v. Ahlers
485 U.S. 197 (Supreme Court, 1988)
In Re Armstrong World Industries, Inc.
432 F.3d 507 (Third Circuit, 2005)
Radlax Gateway Hotel, LLC v. Amalgamated Bank
132 S. Ct. 2065 (Supreme Court, 2012)
In Re American Capital Equipment, LLC
688 F.3d 145 (Third Circuit, 2012)
In Re: Barry L. Michael v.
699 F.3d 305 (Third Circuit, 2012)
In Re W.R. Grace & Co.
729 F.3d 311 (Third Circuit, 2013)
In Re Congoleum Corp.
362 B.R. 167 (D. New Jersey, 2007)
In Re Armstrong World Industries, Inc.
348 B.R. 111 (D. Delaware, 2006)
In Re Washington Mutual, Inc.
442 B.R. 314 (D. Delaware, 2011)
In Re PWS Holding Corp.
228 F.3d 224 (Third Circuit, 2000)
Czyzewski v. Jevic Holding Corp.
580 U.S. 451 (Supreme Court, 2017)
Millennium Lab Holdings II LLC v.
945 F.3d 126 (Third Circuit, 2019)
Tribune Company v.
972 F.3d 228 (Third Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
In re: Akorn, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-akorn-inc-ded-2021.